Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 03, 2018 13:31 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces Vabomere™ (meropenem and vaborbactam) Granted New Technology Add-On Payment by CMS

NEW HAVEN, Conn., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
July 11, 2018 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018

NEW HAVEN, Conn., July 11, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
June 13, 2018 16:05 ET | Source: Melinta Therapeutics

Melinta Therapeutics to Present at the JMP Securities Life Sciences Conference

NEW HAVEN, Conn., June 13, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
May 31, 2018 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Demonstrates Breadth of Commercial and Clinical Programs with 20 Presentations at ASM Microbe 2018

NEW HAVEN, Conn., May 31, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
May 29, 2018 16:05 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock

NEW HAVEN, Conn., May 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
May 24, 2018 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference

NEW HAVEN, Conn., May 24, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
May 23, 2018 21:07 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces Pricing of Public Offering of Common Stock

NEW HAVEN, Conn., May 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
May 21, 2018 16:10 ET | Source: Melinta Therapeutics

Melinta Therapeutics Announces Proposed Offering of Common Stock

NEW HAVEN, Conn., May 21, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
May 11, 2018 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Launches New Antibiotic Stewardship Program to Combat Growing Threat of Antimicrobial Resistance

NEW HAVEN, Conn., May 11, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
May 08, 2018 16:01 ET | Source: Melinta Therapeutics

Melinta Therapeutics Reports First Quarter 2018 Financial Results

Strong Product Sales Performance Across Entire Portfolio Continuing to Optimize Operations to Achieve Cost Synergies Important Achievements for Development and Discovery Efforts Including CARB-X...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right